DE60014489D1 - Von Adenovirus abgeleitete Gentransfervehikel, die zumindest ein Element des Adenovirus Typ 35 enthalten - Google Patents

Von Adenovirus abgeleitete Gentransfervehikel, die zumindest ein Element des Adenovirus Typ 35 enthalten

Info

Publication number
DE60014489D1
DE60014489D1 DE60014489T DE60014489T DE60014489D1 DE 60014489 D1 DE60014489 D1 DE 60014489D1 DE 60014489 T DE60014489 T DE 60014489T DE 60014489 T DE60014489 T DE 60014489T DE 60014489 D1 DE60014489 D1 DE 60014489D1
Authority
DE
Germany
Prior art keywords
adenovirus
serotypes
tropism
proteins
type
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60014489T
Other languages
English (en)
Other versions
DE60014489T2 (de
DE60014489T3 (de
Inventor
Abraham Bout
Ronald Vogels
Menzo Jans Emco Havenga
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Vaccines and Prevention BV
Original Assignee
Crucell Holand BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8240209&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60014489(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Crucell Holand BV filed Critical Crucell Holand BV
Publication of DE60014489D1 publication Critical patent/DE60014489D1/de
Publication of DE60014489T2 publication Critical patent/DE60014489T2/de
Application granted granted Critical
Publication of DE60014489T3 publication Critical patent/DE60014489T3/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10345—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6009—Vectors comprising as targeting moiety peptide derived from defined protein from viruses dsDNA viruses
    • C12N2810/6018—Adenoviridae

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE60014489T 1999-05-17 2000-05-16 Von Adenovirus abgeleitete Gentransfervehikel, die zumindest ein Element des Adenovirus Typ 35 enthalten Expired - Lifetime DE60014489T3 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99201545 1999-05-17
EP99201545 1999-05-17

Publications (3)

Publication Number Publication Date
DE60014489D1 true DE60014489D1 (de) 2004-11-11
DE60014489T2 DE60014489T2 (de) 2005-11-24
DE60014489T3 DE60014489T3 (de) 2010-08-12

Family

ID=8240209

Family Applications (4)

Application Number Title Priority Date Filing Date
DE60045138T Expired - Lifetime DE60045138D1 (de) 1999-05-17 2000-05-16 Rekombinantes Adenovirus des Ad26-Serotyps
DE60043126T Expired - Lifetime DE60043126D1 (de) 1999-05-17 2000-05-16 Von Adenovirus abgeleitete Gentransfervehikel, die zumindest ein Element des Adenovirus Typ 35 enthalten
DE60035229T Expired - Lifetime DE60035229T2 (de) 1999-05-17 2000-05-16 Rekombinanter humaner Adenovirus-Serotyp 35
DE60014489T Expired - Lifetime DE60014489T3 (de) 1999-05-17 2000-05-16 Von Adenovirus abgeleitete Gentransfervehikel, die zumindest ein Element des Adenovirus Typ 35 enthalten

Family Applications Before (3)

Application Number Title Priority Date Filing Date
DE60045138T Expired - Lifetime DE60045138D1 (de) 1999-05-17 2000-05-16 Rekombinantes Adenovirus des Ad26-Serotyps
DE60043126T Expired - Lifetime DE60043126D1 (de) 1999-05-17 2000-05-16 Von Adenovirus abgeleitete Gentransfervehikel, die zumindest ein Element des Adenovirus Typ 35 enthalten
DE60035229T Expired - Lifetime DE60035229T2 (de) 1999-05-17 2000-05-16 Rekombinanter humaner Adenovirus-Serotyp 35

Country Status (14)

Country Link
EP (6) EP1681353B1 (de)
JP (2) JP4843145B2 (de)
KR (1) KR100741247B1 (de)
AT (6) ATE519855T1 (de)
AU (1) AU777041B2 (de)
CA (1) CA2372655C (de)
CY (4) CY1106762T1 (de)
DE (4) DE60045138D1 (de)
DK (6) DK1816204T3 (de)
ES (5) ES2372823T3 (de)
IL (3) IL146479A0 (de)
NZ (1) NZ515582A (de)
PT (5) PT1816204E (de)
WO (1) WO2000070071A1 (de)

Families Citing this family (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994128A (en) 1995-06-15 1999-11-30 Introgene B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US20030017138A1 (en) 1998-07-08 2003-01-23 Menzo Havenga Chimeric adenoviruses
US6929946B1 (en) 1998-11-20 2005-08-16 Crucell Holland B.V. Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
US6869936B1 (en) 1999-03-04 2005-03-22 Crucell Holland B.V. Means and methods for fibroblast-like or macrophage-like cell transduction
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
US7094398B1 (en) 1999-06-01 2006-08-22 University Of Washington Recombinant adenoviral vectors expressing chimeric fiber proteins for cell specific infection and genome integration
US6558948B1 (en) 1999-11-23 2003-05-06 Stefan Kochanek Permanent amniocytic cell line, its production and use for the production of gene transfer vectors
EP1191105A1 (de) * 2000-09-25 2002-03-27 Galapagos Genomics B.V. Gentransfervektoren mit einer Gewebsspezifität für T-Lymphozyten
AU6368901A (en) 2000-05-31 2001-12-11 Univ Saskatchewan Modified bovine adenovirus having altered tropism
AU2002223556A1 (en) * 2000-09-20 2002-04-02 Crucell Holland B.V. Transduction of dendritic cells using adenoviral vectors
DE60138403D1 (de) 2000-09-26 2009-05-28 Crucell Holland Bv Adenovirale vektoren für die übertragung von genen in zellen der skelettmuskulatur oder myoblasten
AU2002211087A1 (en) * 2000-10-06 2002-04-15 Crucell Holland B.V. Gene delivery vectors for stem cells
EP1195440A1 (de) * 2000-10-06 2002-04-10 Introgene B.V. Genverabreichung-Vektoren für Stammzellen
DE60234496D1 (de) * 2001-01-04 2010-01-07 Goeran Wadell Virusvektor zur gentherapie
JP2004536572A (ja) 2001-02-23 2004-12-09 セル・ジェネシス・インコーポレイテッド 新規ベクター構築物
AU2003210661A1 (en) * 2002-01-24 2003-09-02 Novartis Ag Fiber shaft modifications for efficient targeting
EA010828B1 (ru) * 2002-04-25 2008-12-30 Круселл Холланд Б.В. Рекомбинантный аденовирусный вектор и способы его получения и применения
CN100374574C (zh) 2002-04-25 2008-03-12 克鲁塞尔荷兰公司 稳定的腺病毒载体及其增殖方法
JP4237449B2 (ja) * 2002-06-05 2009-03-11 国立医薬品食品衛生研究所長 アデノウィルスベクター
EP1553983A2 (de) 2002-10-23 2005-07-20 Crucell Holland B.V. Einstellung für rekombinante adenovirus-basierte impfstoffe
US20080153083A1 (en) 2003-10-23 2008-06-26 Crucell Holland B.V. Settings for recombinant adenoviral-based vaccines
NZ539813A (en) * 2002-12-17 2008-04-30 Crucell Holland Bv A replication defective recombinant adenovirus comprising a antigenic determinant of Plasmodium falciparum wherein the antigenic determinant is SEQ ID 6
CN1934253A (zh) * 2003-07-18 2007-03-21 昂尼克斯药物公司 用于治疗疾病的b亚组腺病毒载体
DE602005015332D1 (de) 2004-02-23 2009-08-20 Crucell Holland Bv Verfahren zur Reinigung von Viren
CN1972958B (zh) * 2004-04-12 2013-01-23 美国政府卫生与公共服务部 应用腺病毒载体诱导免疫应答的方法
RU2448157C2 (ru) 2004-05-26 2012-04-20 Псиоксус Терапьютикс Лимитед Химерные аденовирусы для применения для лечения злокачественного новообразования
US7741099B2 (en) 2004-10-13 2010-06-22 Beth Israel Deaconess Medical Center Inc. Adenoviral vectors and uses thereof
CN102220357B (zh) 2004-11-16 2013-12-25 克鲁塞尔荷兰公司 包含重组病毒载体的多价疫苗
US8574595B2 (en) 2005-04-11 2013-11-05 Crucell Holland B.V. Virus purification using ultrafiltration
AU2006271666B2 (en) 2005-07-22 2011-04-07 Crucell Holland B.V. Cell line for producing coronaviruses
US20100143302A1 (en) * 2006-03-16 2010-06-10 Crucell Holland B.V. Recombinant Adenoviruses Based on Serotype 26 and 48, and Use Thereof
EA019928B1 (ru) 2008-11-03 2014-07-30 Круселл Холланд Б.В. Способ получения аденовирусных векторов
CA2770075C (en) 2009-08-07 2021-08-24 Perrine Martin Composition for treating hbv infection
US20120315696A1 (en) * 2010-02-15 2012-12-13 Alfred Luitjens METHOD FOR THE PRODUCTION OF Ad26 ADENOVIRAL VECTORS
WO2011098592A1 (en) 2010-02-15 2011-08-18 Crucell Holland B.V. Method for the production of ad26 adenoviral vectors
WO2012038367A1 (en) 2010-09-20 2012-03-29 Crucell Holland B.V. Therapeutic vaccination against active tuberculosis
US9168292B2 (en) 2010-09-27 2015-10-27 Crucell Holland B.V. Heterologous prime boost vaccination regimen against malaria
CN102260712B (zh) * 2011-05-31 2013-10-02 北京锤特生物科技有限公司 溶肿瘤能力增强的B型人腺病毒Ad11突变体的构建和应用
AU2013231423B2 (en) 2012-03-12 2018-10-04 Janssen Vaccines & Prevention B.V. Batches of recombinant adenovirus with altered terminal ends
US8932607B2 (en) 2012-03-12 2015-01-13 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
CA2867955C (en) 2012-03-22 2023-02-07 Crucell Holland B.V. Vaccine against rsv
US9119813B2 (en) 2012-03-22 2015-09-01 Crucell Holland B.V. Vaccine against RSV
JP6162224B2 (ja) 2012-05-24 2017-07-12 クルセル ホランド ベー ヴェー 血管組織の形質導入のためのアデノウイルスベクター
WO2014009433A1 (en) 2012-07-10 2014-01-16 Transgene Sa Mycobacterium resuscitation promoting factor for use as adjuvant
JP6333814B2 (ja) 2012-07-10 2018-05-30 トランジェーヌ、ソシエテ、アノニムＴｒａｎｓｇｅｎｅ Ｓ．Ａ． マイコバクテリア抗原ワクチン
WO2014078688A2 (en) 2012-11-16 2014-05-22 Beth Israel Deaconess Medical Center, Inc. Recombinant adenoviruses and use thereof
KR102089121B1 (ko) 2013-03-14 2020-03-13 더 솔크 인스티튜트 포 바이올로지칼 스터디즈 종양살상형 아데노바이러스 조성물
TR201902513T4 (tr) 2013-04-25 2019-03-21 Janssen Vaccines & Prevention Bv Stabilize edilmiş çözünebilir prefüzyon RSV F polipeptitleri.
EA034653B1 (ru) 2013-06-17 2020-03-03 Янссен Вэксинс Энд Превеншн Б.В. Стабилизированные растворимые f-полипептиды rsv перед слиянием
NZ718931A (en) 2013-10-25 2022-10-28 Psioxus Therapeutics Ltd Oncolytic adenoviruses armed with heterologous genes
WO2015104380A1 (en) 2014-01-09 2015-07-16 Transgene Sa Fusion of heterooligomeric mycobacterial antigens
SG11201701745TA (en) 2014-09-03 2017-04-27 Bavarian Nordic As Methods and compositions for enhancing immune responses
DK3656395T5 (da) 2014-09-03 2024-05-27 Janssen Vaccines & Prevention Bv Fremgangsmåder og sammensætninger til at inducere beskyttende immunitet mod filovirusinfektion
PL3197489T3 (pl) 2014-09-26 2021-11-08 Beth Israel Deaconess Medical Center, Inc. Sposoby i kompozycje do indukowania ochronnej odporności przeciwo zakażeniu ludzkim wirusem niedoboru odporności
MX2017005788A (es) 2014-11-04 2017-08-02 Janssen Vaccines & Prevention Bv Vacunas terapeuticas contra el vph16.
PL3283634T3 (pl) 2015-04-14 2019-10-31 Janssen Vaccines & Prevention Bv Rekombinowany adenowirus eksprymujący dwa transgeny z dwukierunkowym promotorem
EP3288573B1 (de) 2015-04-30 2020-02-12 Psioxus Therapeutics Limited Onkolytisches adenovirus das für ein b7 protein kodiert
CN107847581B (zh) 2015-07-07 2022-03-22 扬森疫苗与预防公司 稳定化的可溶性融合前rsv f多肽
WO2017005844A1 (en) 2015-07-07 2017-01-12 Janssen Vaccines & Prevention B.V. Vaccine against rsv
CA2995740A1 (en) 2015-08-20 2017-02-23 Janssen Vaccines & Prevention B.V. Therapeutic hpv18 vaccines
MD3584252T2 (ro) 2015-12-15 2022-01-31 Janssen Vaccines & Prevention Bv Antigene, vectori, compoziții ale virusului imunodeficienței umane și metode de utilizare a acestora
EP3389682B1 (de) 2015-12-17 2021-11-17 Psioxus Therapeutics Limited Anti-tcr-komplex-antikörper oder -fragment codierender adenovirus der gruppe b
CN108699566B (zh) 2016-02-23 2023-06-30 萨克生物研究学院 对病毒动力学影响最小的治疗性腺病毒中的外源基因表达
CA3013637A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies High throughput assay for measuring adenovirus replication kinetics
EA201892250A1 (ru) 2016-04-05 2019-03-29 Янссен Вэксинс Энд Превеншн Б.В. Вакцина против rsv
HUE053027T2 (hu) 2016-04-05 2021-06-28 Janssen Vaccines & Prevention Bv Stabilizált, szolúbilis prefúziós RSV F fehérje, RSV-fertõzés megelõzésében történõ alkalmazásra
US10517944B2 (en) 2016-05-02 2019-12-31 Janssen Vaccines & Prevention B.V. Therapeutic HPV vaccine combinations
ES2836598T3 (es) 2016-05-30 2021-06-25 Janssen Vaccines & Prevention Bv Proteínas F de RSV prefusión estabilizadas
SG11201810549TA (en) 2016-06-16 2018-12-28 Janssen Vaccines & Prevention Bv Hiv vaccine formulation
US11001858B2 (en) 2016-06-20 2021-05-11 Janssen Vaccines & Prevention B.V. Potent and balanced bidirectional promoter
WO2018011196A1 (en) 2016-07-14 2018-01-18 Janssen Vaccines & Prevention B.V. Hpv vaccines
EP3484507A1 (de) 2016-07-15 2019-05-22 Janssen Vaccines & Prevention B.V. Verfahren und zusammensetzungen zur induzierung von schützender immunität gegen eine marburg-virus-infektion
WO2018011198A1 (en) 2016-07-15 2018-01-18 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against a marburg virus infection
EP3503918B1 (de) 2016-08-29 2020-09-30 Psioxus Therapeutics Limited Adenovirus mit bispezifischem t-zell-engager (bite)
GB201713765D0 (en) 2017-08-28 2017-10-11 Psioxus Therapeutics Ltd Modified adenovirus
EP3532082A4 (de) 2016-12-12 2020-08-26 Salk Institute for Biological Studies Auf tumoren gerichtete synthetische adenoviren und verwendungen davon
US11034978B2 (en) 2017-02-09 2021-06-15 Janssen Vaccines & Prevention B.V. Potent and short promoter for expression of heterologous genes
US11173204B2 (en) 2017-04-06 2021-11-16 Janssen Vaccines & Prevention B.V. MVA-BN and Ad26.ZEBOV or Ad26.filo prime-boost regimen
WO2018210871A1 (en) 2017-05-17 2018-11-22 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against rsv infection
EP3624844A1 (de) 2017-05-17 2020-03-25 Janssen Vaccines & Prevention B.V. Verfahren und zusammensetzungen zur induzierung schützender immunität gegen rsv-infektionen
CN110958887B (zh) 2017-06-15 2023-10-31 扬森疫苗与预防公司 编码hiv抗原的痘病毒载体及其使用方法
EA202090738A1 (ru) 2017-09-15 2020-06-10 Янссен Вэксинс Энд Превеншн Б.В. Способ безопасного индуцирования иммунитета против rsv
WO2019099970A1 (en) 2017-11-20 2019-05-23 Janssen Pharmaceuticals Inc. Method of providing safe administration of adenoviral vectors encoding a zika virus antigen
EP3723771A4 (de) 2017-12-11 2022-04-06 Beth Israel Deaconess Medical Center, Inc. Rekombinante adenoviren und verwendungen davon
WO2019123250A1 (en) 2017-12-19 2019-06-27 Janssen Sciences Ireland Unlimited Company Methods and compositions for inducing an immune response against hepatitis b virus (hbv)
EP3810277A1 (de) 2018-07-20 2021-04-28 Janssen Vaccines & Prevention B.V. Rekombinanter adenoviraler vektor, der ein zika-antigen mit verbesserter produktivität exprimiert
MX2021008392A (es) 2019-01-10 2021-10-26 Janssen Biotech Inc Neoantígenos prostaticos y sus usos.
KR20220008816A (ko) 2019-05-15 2022-01-21 얀센 백신스 앤드 프리벤션 비.브이. 아데노바이러스 기반 백신을 사용한 호흡기 세포융합 바이러스 감염의 예방적 치료
EP3969044A1 (de) 2019-05-15 2022-03-23 Janssen Vaccines & Prevention B.V. Gleichzeitige verabreichung eines saisonalen grippeimpfstoffs und eines adenovirus-basierten impfstoffs gegen das respiratorische synzytialvirus
PE20221182A1 (es) 2019-11-18 2022-08-05 Janssen Biotech Inc Vacunas basadas en calr y jak2 mutantes y sus usos
TW202144388A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在卵巢癌中表現之新抗原及其用途
TW202144389A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在多發性骨髓瘤中表現之新抗原及其用途
CN111337042B (zh) * 2020-03-13 2021-11-02 湖北大学 一种车辆路径规划方法及系统
US20210315986A1 (en) 2020-04-13 2021-10-14 Janssen Biotech, Inc. Psma and steap1 vaccines and their uses
US20230024133A1 (en) 2020-07-06 2023-01-26 Janssen Biotech, Inc. Prostate Neoantigens And Their Uses
EP4176087A1 (de) 2020-07-06 2023-05-10 Janssen Biotech, Inc. Verfahren zur bestimmung des ansprechens auf eine prostatakrebsbehandlung
WO2022009052A2 (en) 2020-07-06 2022-01-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
CA3188801A1 (en) 2020-07-08 2022-01-13 Janssen Sciences Ireland Unlimited Company Rna replicon vaccines against hbv
GB202013940D0 (en) 2020-09-04 2020-10-21 Synpromics Ltd Regulatory nucleic acid sequences
CA3195177A1 (en) 2020-10-07 2022-04-14 Asklepios Biopharmaceutical, Inc. Therapeutic adeno-associated virus delivery of fukutin related protein (fkrp) for treating dystroglycanopathy disorders including limb girdle 2i (lgmd2i)
EP4267605A2 (de) 2020-12-23 2023-11-01 Janssen Biotech, Inc. Neoantigen-peptid-mimetika
WO2023198815A1 (en) 2022-04-14 2023-10-19 Janssen Vaccines & Prevention B.V. Sequential administration of adenoviruses

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2725726B1 (fr) * 1994-10-17 1997-01-03 Centre Nat Rech Scient Vecteurs viraux et utilisation en therapie genique
US5856152A (en) * 1994-10-28 1999-01-05 The Trustees Of The University Of Pennsylvania Hybrid adenovirus-AAV vector and methods of use therefor
US5994128A (en) 1995-06-15 1999-11-30 Introgene B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US5837511A (en) * 1995-10-02 1998-11-17 Cornell Research Foundation, Inc. Non-group C adenoviral vectors
US5877011A (en) * 1996-11-20 1999-03-02 Genzyme Corporation Chimeric adenoviral vectors
US6100086A (en) * 1997-04-14 2000-08-08 Genzyme Corporation Transgene expression systems
JP4683727B2 (ja) * 1999-03-04 2011-05-18 クルーセル ホランド ベスローテン フェンノートシャップ 線維芽細胞様またはマクロファージ様細胞の形質導入のための手段と方法
JP2011521985A (ja) * 2008-06-03 2011-07-28 オカイロス アーゲー Ｈｃｖ感染の予防および治療のためのワクチン

Also Published As

Publication number Publication date
NZ515582A (en) 2003-11-28
JP5335037B2 (ja) 2013-11-06
ES2354578T3 (es) 2011-03-16
EP1818408A1 (de) 2007-08-15
DE60045138D1 (de) 2010-12-02
DK1054064T4 (da) 2010-05-03
CA2372655C (en) 2011-11-15
EP1054064B1 (de) 2004-10-06
DK1816205T3 (da) 2011-11-21
EP1816205B1 (de) 2011-08-10
DK1818408T3 (da) 2011-10-17
PT1550722E (pt) 2007-09-25
IL214413A0 (en) 2011-09-27
ATE364707T1 (de) 2007-07-15
EP1681353A1 (de) 2006-07-19
JP2002543846A (ja) 2002-12-24
EP1818408B1 (de) 2011-08-10
EP1681353B1 (de) 2009-10-07
KR100741247B1 (ko) 2007-07-19
EP1816204B1 (de) 2010-10-20
CA2372655A1 (en) 2000-11-23
JP2011224014A (ja) 2011-11-10
EP1054064B2 (de) 2009-12-16
CY1112008T1 (el) 2015-11-04
IL214413A (en) 2014-04-30
ATE485382T1 (de) 2010-11-15
AU777041B2 (en) 2004-09-30
CY1106762T1 (el) 2012-05-23
ATE278792T1 (de) 2004-10-15
DE60035229D1 (de) 2007-07-26
EP1550722A1 (de) 2005-07-06
CY1111494T1 (el) 2015-08-05
IL146479A0 (en) 2002-07-25
ES2372824T3 (es) 2012-01-26
DE60014489T2 (de) 2005-11-24
EP1550722B1 (de) 2007-06-13
DE60014489T3 (de) 2010-08-12
AU4954700A (en) 2000-12-05
ES2289426T3 (es) 2008-02-01
PT1054064E (pt) 2005-02-28
EP1816205A1 (de) 2007-08-08
DE60035229T2 (de) 2008-02-21
IL146479A (en) 2011-12-29
ATE519854T1 (de) 2011-08-15
PT1816204E (pt) 2011-01-24
CY1112189T1 (el) 2015-12-09
EP1054064A1 (de) 2000-11-22
DK1681353T3 (da) 2010-01-04
DE60043126D1 (de) 2009-11-19
EP1816204A1 (de) 2007-08-08
PT1818408E (pt) 2011-11-15
PT1816205E (pt) 2011-11-15
ES2231103T5 (es) 2010-04-15
DK1816204T3 (da) 2011-01-24
ES2231103T3 (es) 2005-05-16
JP4843145B2 (ja) 2011-12-21
KR20020028879A (ko) 2002-04-17
ATE519855T1 (de) 2011-08-15
DK1054064T3 (da) 2005-01-10
ATE445018T1 (de) 2009-10-15
WO2000070071A1 (en) 2000-11-23
DK1550722T3 (da) 2007-10-08
ES2372823T3 (es) 2012-01-26

Similar Documents

Publication Publication Date Title
ATE278792T1 (de) Von adenovirus abgeleitete gentransfervehikel, die zumindest ein element des adenovirus typ 35 enthalten
ATE278789T1 (de) Hilfsfunktionen fuer die rekombinante aav- virionherstellung
WO2000073478A3 (en) Recombinant adenoviral vectors expressing chimeric fiber proteins for cell specific infection and genome integration
WO2003099859A3 (de) Neue verwendung von adenoviren und dafür codierenden nukleinsäuren
EP1270586A3 (de) Zusammensetzung zum zellspezifischen Transfer von Wirkstoffen
AU2002228805A1 (en) Antisense modulation of damage-specific dna binding protein 2, p48 expression
ATE293160T1 (de) Nicht-embryonale ependymale neuronale stammzellen und methoden zu ihrer isolierung
WO2006086357A3 (en) Adenovirus serotype 36 vectors, nucleic acid and viruses produced thereby
WO2002083896A3 (en) Recombinant segmented negative strand virus with a duplicated 3' noncoding flanking sequence, and therapeutic compositions containing the same
WO2002083902A3 (en) Adenovirus serotype 30 (ad30) fiber protein and uses thereof
ATE428793T1 (de) Adenovirale vektoren für die übertragung von genen in zellen der skelettmuskulatur oder myoblasten
WO2001077293A3 (en) Gp40 and uses thereof
Chin Rescuing Glycine
Powers Raising Caen.
Asgharian et al. A comparative monomolecular film study of 1, 2-di-O-palmitoyl-3-O-(. alpha.-and. beta.-D-glucopyranosyl)-sn-glycerols [Erratum to document cited in CA111 (11): 92542q]
Nishida From Cell Motility to Cell Biology
坂口実 TWO-PERSON HI-LO POKER: STUD AND DRAW, II
Heldin Different Dimeric Forms of PDGF have Different Functional Activities
Banks The upper airway.
Kacich et al. The papers are brief and well illustrated. The section on megacolon, an unusual adult abnormality, is particularly well done. This is a report of a meeting and not an authoritative, complete monograph on surgery of the colon and rectum. The cost in paperback is $30, and would be
Sato Mechanism of angiogenesis

Legal Events

Date Code Title Description
8363 Opposition against the patent
8366 Restricted maintained after opposition proceedings